# Peckforton Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/peckforton-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: UK
- Website: www.peckforton.com
- Total disclosed funding: $2.4M
- Latest round: Series B (Dec 1, 2007)
- Investors on record: 2

## About

Peckforton Pharmaceuticals Ltd. is a UK-based company specializing in pharmaceutical solutions. It focuses on developing innovative products aimed at improving health outcomes across various sectors.Founded in 1995, Peckforton Pharmaceuticals Ltd. operates in the pharmaceutical industry, providing specialized health solutions. The company was acquired by Abbey Pharmaceuticals on August 11, 2014, as part of a strategic move to enhance its market position. Based in the UK, Peckforton has conducted a total of 3 deals, raising a total of GBP 1.000 mn through its latest funding round supported by Mercia Asset Management and YFM Equity Partners.Peckforton Pharmaceuticals offers specialized pharmaceutical products designed to meet the needs of health practitioners and patients. The company aims to enhance health outcomes through innovative solutions, addressing specific health challenges. Its clientele includes healthcare providers and institutions, both locally and internationally, with a focus on regions experiencing significant health service demands, such as Europe and parts of Asia.In the most recent fiscal year of 2020, Peckforton Pharmaceuticals reported a revenue of GBP 6,012,779 and an EBITDA of GBP 3,470,908. The company generates revenue through various models, including B2B partnerships and direct-to-consumer sales, with a strong emphasis on subscription-based services for accessing premium features and support.Peckforton Pharmaceuticals plans to launch new health solutions designed to address emerging health challenges, although specific release dates have not been disclosed. The company is targeting expansion into new markets, particularly in North America and Asia, by 2025. The recent funding round will be utilized to support these initiatives, allowing the company to develop new products and enhance its market presence following the acquisition by Abbey Pharmaceuticals.

## Funding rounds

- Series B, Dec 1, 2007, $2.4M — YFM Equity Partners, Mercia Asset Management

## Investors

- YFM Equity Partners (https://capitalatlas.ai/funds/yfm-equity-partners) — Series B
- Mercia Asset Management (https://capitalatlas.ai/funds/mercia-asset-management) — Series B